Lucid Diagnostics (NASDAQ:LUCD) Posts Earnings Results

Lucid Diagnostics (NASDAQ:LUCDGet Free Report) released its earnings results on Monday. The company reported ($0.26) earnings per share (EPS) for the quarter, Yahoo Finance reports. Lucid Diagnostics had a negative return on equity of 8,334.14% and a negative net margin of 2,169.07%. The firm had revenue of $1.04 million during the quarter. During the same period last year, the company earned ($0.22) earnings per share.

Lucid Diagnostics Price Performance

Shares of LUCD stock opened at $0.99 on Wednesday. The company has a market capitalization of $44.22 million, a price-to-earnings ratio of -0.78 and a beta of 1.73. The company’s fifty day moving average price is $1.30 and its 200-day moving average price is $1.34. Lucid Diagnostics has a one year low of $0.97 and a one year high of $1.85.

Institutional Investors Weigh In On Lucid Diagnostics

Institutional investors have recently bought and sold shares of the business. Citadel Advisors LLC boosted its stake in shares of Lucid Diagnostics by 14.6% in the third quarter. Citadel Advisors LLC now owns 35,333 shares of the company’s stock worth $54,000 after acquiring an additional 4,506 shares during the period. BlackRock Inc. boosted its stake in Lucid Diagnostics by 39.5% in the 2nd quarter. BlackRock Inc. now owns 26,304 shares of the company’s stock worth $37,000 after purchasing an additional 7,448 shares during the period. Verition Fund Management LLC grew its holdings in Lucid Diagnostics by 29.2% during the 2nd quarter. Verition Fund Management LLC now owns 46,709 shares of the company’s stock valued at $106,000 after buying an additional 10,543 shares in the last quarter. State Street Corp grew its holdings in Lucid Diagnostics by 24.4% during the 1st quarter. State Street Corp now owns 56,693 shares of the company’s stock valued at $190,000 after buying an additional 11,121 shares in the last quarter. Finally, LPL Financial LLC raised its position in shares of Lucid Diagnostics by 97.2% during the third quarter. LPL Financial LLC now owns 28,400 shares of the company’s stock valued at $33,000 after buying an additional 14,000 shares during the last quarter. Hedge funds and other institutional investors own 74.01% of the company’s stock.

About Lucid Diagnostics

(Get Free Report)

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma (EAC). It offers EsoCheck, a cell collection device to prevent EAC deaths; and EsoGuard, an Esophageal DNA Test.

Featured Articles

Earnings History for Lucid Diagnostics (NASDAQ:LUCD)

Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.